SLC2A1 and glioblastoma: Knocking out ZDHHC9 using the CRISPR/Cas9 system or mutating the GLUT1 palmitoylation site abolished palmitoylation and cell membrane distribution of GLUT1, resulting in impaired glycolysis, cell proliferation, and GBM tumorigenesis [13] (Fig. 2, Table 1).